Pre-made Mitumomab benchmark antibody (Whole mAb, anti-ganglioside GD3 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Anti-ganglioside GD3 therapeutic antibody (Pre-made Mitumomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck.[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-916-1mg	1mg	3090
GMP-Bios-INN-916-10mg	10mg	Inquiry
GMP-Bios-INN-916-100mg	100mg	Inquiry
GMP-Bios-INN-916-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Mitumomab Biosimilar, Whole Mab: Anti-Ganglioside Gd3 therapeutic antibody
INN Name	Mitumomab
Target	ganglioside GD3
Format	Whole mAb
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	IgG2b - kappa
VD LC	IgG2b - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Merck KgaA (Darmstadt Germany) / ImClone Systems Inc. (Somerville NJ USA) / Memorial Sloan-Kettering Cancer Center (New York NY USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0